Critiquing https://theotherburzynskipatientgroup.wordpress.com

Critiquing https://theotherburzynskipatientgroup.wordpress.com

Robert J. (Bob) Blaskiewicz operates The Other Burzynski Patient Group (TOBPG)

The problem is:

1. Bob Blaskiewicz Faux Skeptic Exposed! does NOT want to debate or want people to consider the failures of Science Based Medicine compared to Burzynski, because he has an agenda

2. @rjblaskiewicz is a known LIAR

Making unsubstantiated claims like this:

Bob Blaskiewicz (@rjblaskiewicz) tweeted at 9:45am – 25 Aug 13:

@dixon_frederick @AlaaTheWarrior Actually, he CLAIMS a success rate, but is unable to publish. Suspicious: clinicaltrials.gov/ct2/results?te…

� � � � � � � � � � � � � � � � �
374 – TOTAL CHILDREN DIED:
Science Based Medicine

� � � � � � � � � � � � � � � � �
======================================
[6] .9/15/1999 – 29 / 85% died
======================================
[9] .9/15/1994 – 51 / 88% – children died
======================================
[8] 1/1998 – 8 / 89% of 9 children died of their disease at median of 44 weeks
======================================
[5] .10/21/2002 – 12 / 100% – all children patients died
======================================
[2] 5/1/2010 – 18 – children patients have died from disease progression
======================================
[3] 2/2008 – All 30 / 100% – children have died
======================================
[4] 1/1/2005 – 33 / 100% – children died of disease progression
======================================
[1] 4/2011 – 63 / 100% – children died
======================================
[7] .3/15/1999 – 130 / 100% – children died
======================================
� � � � � � � � � � � � � � � � �
======================================
COMBINED:
======================================
� � � � � � � � � � � � � � � � �
======================================
[1] 4/2011 – children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)
——————————————————————
[1] 4/2011 – children with DIPG
——————————————————————
[1] 5/1/2010 children with newly diagnosed diffuse intrinsic pontine glioma
——————————————————————
[1] 5/1/2010 children with diffuse intrinsic pontine gliomas (DIPGs)
——————————————————————
[1] 5/1/2010 Pediatric patients with newly diagnosed DIPGs
——————————————————————
[3] 2/2008 – children with diffuse intrinsic brain stem glioma
——————————————————————
[3] 2/2008 – diffuse intrinsic pontine glioma
——————————————————————
[4] 1/1/2005 – newly diagnosed diffuse brainstem glioma in children
——————————————————————
[4] 1/1/2005 – children with newly diagnosed diffuse brainstem glioma
——————————————————————
[4] 1/1/2005 – newly diagnosed, diffuse, intrinsic brain stem glioma
——————————————————————
[5] .10/21/2002 – typical diffuse pontine glioma
or
histologically proven anaplastic astrocytoma/glioblastoma multiforme located in the pons

——————————————————————
[5] .10/21/2002 – pontine glioma patients
——————————————————————
[5] .10/21/2002 – paediatric patients with pontine gliomas
——————————————————————
[5] .10/21/2002
brain tumours
brain stem glioma

——————————————————————
[5] .10/21/2002
Histological diagnoses included

8 – glioblastoma multiforme
5 – no histology
3 – anaplastic astrocytoma
3 – astrocytoma with no other specification
1 – pilocytic astrocytoma

——————————————————————
[6] .9/15/1999 – Brainstem gliomas
——————————————————————
[6] .9/15/1999 – diffuse intrinsic pontine tumor
——————————————————————
[6] .9/15/1999 – high grade glioma was required for nonpontine brain stem tumors
——————————————————————
[7] .3/15/1999 children with newly diagnosed brainstem tumor
——————————————————————
[7] .3/15/1999 tumors arising in the pons
——————————————————————
[7] .3/15/1999 diffusely infiltrating pontine lesion
——————————————————————
[8] 1/1998 – children with diffuse pontine gliomas
——————————————————————
[8] 1/1998 – pediatric malignancies
——————————————————————
[8] 1/1998 – Diffuse pontine gliomas
——————————————————————
[9] .9/15/1994 – Brain stem gliomas
——————————————————————
[9] .9/15/1994 – childhood brain tumors
——————————————————————
[9] .9/15/1994 – children with brain stem gliomas
——————————————————————
[9] .9/15/1994 – patients with diffuse intrinsic brain stem gliomas
——————————————————————
[9] .9/15/1994 – children with diffuse intrinsic brain stem gliomas
======================================
� � � � � � � � � � � � � � � � �
======================================
# OF CHILDREN
======================================
� � � � � � � � � � � � � � � � �
======================================
[8] 1/1998 – 9 / 100% – consecutive children
——————————————————————
[5] .10/21/2002 – 20 – enrolled (9 male / 11 female)
——————————————————————
[2] 5/1/2010 – 20 – children accrued
——————————————————————
[3] 2/2008 – 31 – children enrolled
——————————————————————
[4] 1/1/2005 – 33 / 100% – patients enrolled
——————————————————————
[6] .9/15/1999 – 34 / 100% – patients enrolled
——————————————————————
[1] 4/2011 – 63 / 100% – children enrolled in study
——————————————————————
[9] .9/15/1994 – 66 children
——————————————————————
[7] .3/15/1999
130 – eligible patients
66 – arm 1
64 – arm 2
======================================
� � � � � � � � � � � � � � � � �
======================================
# OF EVALUABLE CHILDREN
======================================
� � � � � � � � � � � � � � � � �
======================================
[8] 1/1998 – 9 / 100% – consecutive children evaluable
——————————————————————
[5] .10/21/2002 – 12 – Evaluable patients
——————————————————————
[2] 5/1/2010 – 20 – children evaluable
——————————————————————
[3] 2/2008 – 30 – eligible and evaluable for survival and toxicity
——————————————————————
[4] 1/1/2005 – 33 / 100% – patients evaluable
——————————————————————
[6] .9/15/1999 – 34 / 100% – patients evaluable
——————————————————————
[9] .9/15/1994 – 58 / 100% – evaluable patients
——————————————————————
[1] 4/2011 – 63 / 100% – children evaluable
——————————————————————
[7] .3/15/1999
130 – evaluable patients
66 – arm 1
64 – arm 2
======================================
� � � � � � � � � � � � � � � � �
======================================
AGE RANGE OF CHILDREN
======================================
� � � � � � � � � � � � � � � � �
======================================
[5] .10/21/2002 – 3-17 years of age
——————————————————————
[6] .9/15/1999 – 3.6–15.4 years
——————————————————————
[3] 2/2008 – 3–21 – age children enrolled
——————————————————————
[4] 1/1/2005 – 3-21 years – eligible for current multiinstitutional study
——————————————————————
[7] .3/15/1999 3-21 years of age
======================================
� � � � � � � � � � � � � � � � �
======================================
MEDIAN AGE OF CHILDREN
======================================
� � � � � � � � � � � � � � � � �
======================================
[5] .10/21/2002 – 6 years – median age
——————————————————————
[4] 1/1/2005 – 6.4 years – Median age at diagnosis
——————————————————————
[9] .9/15/1994 – 7.5 years – mean age at diagnosis
——————————————————————
[6] .9/15/1999 – 7.8 years – median age of patients
——————————————————————
[3] 2/2008 – 8 – median age (3–14 years)
——————————————————————
[2] 5/1/2010 – 8.3 years – mean age
======================================
� � � � � � � � � � � � � � � � �
======================================
1 YEAR OR LESS SURVIVAL RATES
======================================
� � � � � � � � � � � � � � � � �
======================================
[1] 4/2011 – 9 / 14% – mean 1-year Event-Free Survival (EFS)
——————————————————————
[1] 4/2011 – 14 / 21.9% – no evidence produced 1-year Event-Free Survival (EFS) rate higher than
——————————————————————
10/2006..5 / 26% – 1 year: Burzynski Antineoplastons: Progression-Free Survival Rate (PFS): Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG) (Pg. 466)
——————————————————————
[7] 3/15/1999 – 17 / 27.0% – ARM 2: 1 year Patients Surviving: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
10/2004..9 / 29%Burzynski Antineoplastons: 1 year Progression-Free Survival (PFS): Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG): Special Exception (SE) (Pg. 386)
——————————————————————
[7] 3/15/1999 – 40 / 30.9% – ARM 1: 1 year Patients Surviving: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
[9] .9/15/1994 – 20 / 35% – 1 year Overall Survival
——————————————————————
3/2006..39%Burzynski Antineoplastons Patients with high-grade, recurrent and progressive BRAINSTEM GLIOMAS: Progression-Free Survival (PFS) at 6 months: BRAINSTEM GLIOMA (BSG) (Pgs. 40 + 44-45)
——————————————————————
[1] 4/2011 – 25 / 40% – mean 1-year Overall Survival (OS)
——————————————————————
10/2004..12 / 41%Burzynski l: 1 year Progression-Free Survival (PFS): Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) (Pg. 386)
——————————————————————
3/2004 – 43%Burzynski Antineoplastons – % of responding Patients didn’t develop Progression: 6/1/2003 Protocol – BT-11 – BRAIN STEM GLIOMA (Pg. 51)
——————————————————————
[4] 1/1/2005 – 16 / 48% – 1 year estimated Survival rate
——————————————————————
10/2006..10 / 53%Burzynski Antineoplastons 1 year Overall Survival Rate (OS): Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG) (Pg. 466)
——————————————————————
3/2004 – 61%Burzynski Antineoplastons % of Objective Response (OR) Patients hadn’t had Progression: 6/1/2003 Protocol – HIGH-GRADE GLIOMA (Pg. 53)
——————————————————————
[3] 2/2008 – 27 / 90% – 1 year  - Overall survival
======================================
� � � � � � � � � � � � � � � � �
======================================
LESS THAN 1 YEAR SURVIVAL (MST)
======================================
� � � � � � � � � � � � � � � � �
======================================
[7] 3/15/1999 – 5 months – ARM 2: Median time to Disease Progression: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
3/2006.-.6 months – Patients with Recurrent Tumors Survive no more than, despite standard treatment: (Pgs. 40 + 45-46)
——————————————————————
[7] 3/15/1999 – 6 months – ARM 1: Median time to Disease Progression: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
2003 – 6.4 monthsBurzynski Antineoplastons Median Survival: Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 Special Exception (SE) (Pg. 99)
——————————————————————
2003 – 7 monthsBurzynski Antineoplastons Median Survival: Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pg. 99)
——————————————————————
3/2004 – 7 monthsBurzynski Antineoplastons – Progression-Free Survival (PFS): 6/1/2003 Protocol – BT-11 BRAIN STEM GLIOMA (Pg. 51)
——————————————————————
3/2004 – 7 monthsBurzynski Antineoplastons Progression-Free Survival (PFS): Protocol – subgroup very difficult to treat recurrent diffuse intrinsic BRAIN STEM GLIOMA (Pg. 52)
——————————————————————
[7] 3/15/1999 – 8 months – ARM 2: Median time to Death: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992 – 10/1997) 2004 (Pg. 58)
——————————————————————
[7] 3/15/1999 – 8 months – ARM 2: Median Overall Survival from Diagnosis (OSD): Median time to Death: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
[7] 3/15/1999 – 8 months – ARM 2: Median Overall Survival from start of Treatment (OST): Median time to Death: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
[7] 3/15/1999 – 8.5 months – Median Survival (MST): standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al.) (6/1992–10/1997) children with newly diagnosed diffuse intrinsic BRAIN STEM TUMORS: results of pediatric oncology group
——————————————————————
[7] 3/15/1999 – 8.5 months – ARM 1: Median Overall Survival from start of Treatment (OST): Median time to Death: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
[7] 3/15/1999 – 8.5 months – ARM 1: Median time to Death: Median Overall Survival from Diagnosis (OSD): Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
3/2004 – 10.3 monthsBurzynski Antineoplastons – Median Overall Survival from start of Treatment (OST): 6/1/2003 Protocol – BT-11 BRAIN STEM GLIOMA (Pg. 51)
======================================
� � � � � � � � � � � � � � � � �
======================================
1 YEAR SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2004 – 12 months (1 year)Burzynski Antineoplastons: Progression-Free Survival (PFS): 6/1/2003 Protocol – HIGH-GRADE GLIOMA (Pg. 53)
======================================
� � � � � � � � � � � � � � � � �
======================================
1+ YEAR SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2004 – 13.7 months (1 year 1.7 months)Burzynski Antineoplastons: Median Overall Survival from Diagnosis (OSD): 6/1/2003 Protocol – BT-11 BRAIN STEM GLIOMA (Pg. 51)
——————————————————————
4/2007 – 16.4 months (1 year 4.4 months)Burzynski Antineoplastons(ANP): Median Survival (MST): Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) BT-11 (Pg. 206)
——————————————————————
3/2004 – 17 months (1 year 5 months) – Median Survival without Treatment (Pg. 53)
——————————————————————
2006 – 19.9 months (1 year 7.9 months) – Median Survival Time (MST): next best traditional standard of care study (Pg. 172)
——————————————————————
2006 – 19.9 months (1 year 7.9 months)Burzynski Antineoplastons (ANP): Median Survival Time (MST): Treatments for Astrocytic Tumors – recurrent and progressive tumor: Treatment of diffuse, intrinsic BRAINSTEM GLIOMA in children (Pg. 172)
======================================
� � � � � � � � � � � � � � � � �
======================================
2 YEAR SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2006 – 2 years – Most Patients with BRAINSTEM GLIOMA fail standard radiation therapy and chemotherapy and don’t survive longer: (Pgs. 40 + 45-46)
——————————————————————
[7] 3/15/1999 – 4 / 6.7% – ARM 2: 2 year Patients Surviving: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
[7] 3/15/1999 – 7% – 2 year Overall Survival (OS): standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al.) (6/1992–10/1997) children with newly diagnosed diffuse intrinsic BRAIN STEM TUMORS: results of pediatric oncology group
——————————————————————
[7] 3/15/1999 – 9 / 7.1% – ARM 1: 2 year Patients Surviving: Protocol – easier to treat cases of newly diagnosed BRAIN STEM (tumor) GLIOMA patients: radiation therapy and chemotherapy with cisplatin (Mandell et al.) (6/1992–10/1997) 2004 (Pg. 58)
——————————————————————
Less than 10% – 2 year Survival: standard radiation therapy: for newly diagnosed diffuse intrinsic BRAIN STEM GLIOMA (DBSG)
——————————————————————
[3] 2/2008 – 3 / 10% – 2 years – Overall survival
——————————————————————
10/2006..3 / 16% – 2 years: Burzynski Antineoplastons: Progression-Free Survival Rate (PFS): Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG) (Pg. 466)
——————————————————————
10/2006..6 / 32% – 2 year Overall Survival Rate (OS): Burzynski Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG) (Pg. 466)
——————————————————————
2003 – 4 / 33.3% – 2 year Survival: Burzynski Antineoplastons Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pgs. 91-92)
——————————————————————
3/2006 – 39% – 2 year Overall Survival: Burzynski Antineoplastons: Patients with high-grade, recurrent and progressive BRAINSTEM GLIOMAS (BSG) (Pgs. 40 + 44-45)
——————————————————————
4/2007 – 8 / 40% – 2 year Overall Survival (OS): Burzynski Antineoplastons (ANP): Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) BT-11 (Pg. 206)
——————————————————————
2004 – 42% – 2 year Patients (Surviving) Survival: Burzynski Antineoplastons: 6/1/2003 Protocol – BRAIN STEM GLIOMA (Pgs. 52-53)
——————————————————————
10/2004..13 / 45% – 2 year Overall Survival (Survival: Special Exception (SE)) Burzynski Antineoplastons: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) (Pg. 386)
——————————————————————
2006 – 14 / 46.7% – 2 year Overall Survival (OS) (%) – Efficacy: Burzynski Antineoplastons (ANP): Treatments for Astrocytic Tumors – recurrent and progressive tumor: Treatment of diffuse, intrinsic BRAINSTEM GLIOMA in children (Pg. 172)
——————————————————————
2006 – 30 / 46.7% – 2 year Overall Survival (OS) (%) – Efficacy: next best traditional standard of care study (Pg. 172)
——————————————————————
7/2005 – 5 / 50% – 2 year Overall Survival: Burzynski Antineoplastons: children less than 4 years old with inoperable BRAIN STEM GLIOMAs (BSG) BT-11 (study and Special Exception (SE)) (Pg. 300)
——————————————————————
2006 – 6 / 60% – 2 year Overall Survival (OS) (%) – Efficacy: Burzynski Antineoplastons (ANP) – recurrent and progressive (RPS) tumors in children aged <4y: children less than 4 years old with inoperable BRAIN STEM GLIOMAS (Pg. 172) 2005
——————————————————————
2006 – 6 / 60% – 2-year Survival rate: Burzynski Antineoplastons (ANP) – children aged <4 years diagnosed with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) treated with ANP (Pg. 173) 2005
� � � � � � � � � � � � � � � � �
======================================
2+ YEARS PATIENTS SURVIVED
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2006 – 2+ years – Most Patients with Newly Diagnosed High-Grade BRAIN STEM GLIOMAS (HBSG) don’t Survive more than: (Pgs. 40 + 45-46)
——————————————————————
2006 – 12 / >40% – 2+ year patients survived Burzynski Antineoplastons (ANP) recurrent and progressive diffuse intrinsic BRAINSTEM GLIOMA (DBSG) (Pg. 173)
======================================
� � � � � � � � � � � � � � � � �
======================================
3 YEAR OVERALL SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
[9] .9/15/1994 – 7 / 11% – 3 years Overall Survival
======================================
� � � � � � � � � � � � � � � � �
======================================
4+ YEARS FROM START OF TREATMENT
======================================
� � � � � � � � � � � � � � � � �
======================================
2003 – 4+ years – 1 alive – From start of Treatment: Burzynski Antineoplastons Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pgs. 91-92)
======================================
� � � � � � � � � � � � � � � � �
======================================
LONG TERM SURVIVORS
======================================
� � � � � � � � � � � � � � � � �
======================================
2003 – 5+ years – 1 alive – Burzynski Antineoplastons: From start of Treatment: Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pgs. 91-92)
——————————————————————
[7] 3/15/1999 – 0% – 5 year Overall Survival (OS): standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al.) (6/1992–10/1997) children with newly diagnosed diffuse intrinsic BRAIN STEM TUMORS: results of pediatric oncology group
——————————————————————
[6] .9/15/1999 – 5 / 15% – long term survivors who remained in continuous remission after mean follow-up period of 79 months {6 years 7 months} (46–104 months [3 years 10 months – 8 years 8 months])
——————————————————————
10/2006..3 / 16% – 5 year Overall Survival Rate (OS): Burzynski Antineoplastons: Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG) (Pg. 466)
——————————————————————
10/2004..5 / 16% – 5 years: Burzynski Antineoplastons: Overall Survival (Survival: Special Exception (SE)) Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG): Special Exception (SE) (Pg. 386)
——————————————————————
7/2005 – 2 / 20% – 5 year Overall Survival: Burzynski Antineoplastons: children less than 4 years old with inoperable BRAIN STEM GLIOMAs (BSG) BT-11 (study and Special Exception (SE)) (Pg. 300)
——————————————————————
2005 – 2 / 20% – 5 year Overall Survival (OS) (%) – Efficacy: Burzynski Antineoplastons (ANP) – recurrent and progressive (RPS) tumors in children aged <4y: children less than 4 years old with inoperable BRAIN STEM GLIOMAS 2006 (Pg. 172)
——————————————————————
2005 – 2 / 20% – 5-year Survival rate: 2006 Burzynski Antineoplastons (ANP) – children aged <4 years diagnosed with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) treated with ANP (Pg. 173)
——————————————————————
3/2006 – 22%Burzynski Antineoplastons 5 year Overall Survival: Patients with high-grade, recurrent and progressive BRAINSTEM GLIOMAS (BSG) (Pgs. 40 + 44-45)
——————————————————————
10/2004..7 / 24% – 5 years: Burzynski Antineoplastons: Overall Survival (Survival: Special Exception (SE)) Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) (Pg. 386)
——————————————————————
4/2007 – 6 / 30% – 5 year Overall Survival (OS): Burzynski Antineoplastons ((ANP): Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG) BT-11 (Pg. 206)
——————————————————————
2005 – 9 / 30% – 5 year Overall Survival (OS) (%) – Efficacy: Burzynski Antineoplastons (ANP): Treatments for Astrocytic Tumors – recurrent and progressive tumor: Treatment of diffuse, intrinsic BRAINSTEM GLIOMA in children 2006 (Pg. 172)
——————————————————————
2005 – 9 / 30% – 5+ year patients survived Burzynski Antineoplastons (ANP) recurrent and progressive diffuse intrinsic BRAINSTEM GLIOMA (DBSG) 2006 (Pg. 173)
——————————————————————
2003 – 2 / 17% – 5+ years Alive and Tumor Free since Initial Diagnosis: Burzynski Antineoplastons: Protocol patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA: BT-11 (Pgs. 91-92)
——————————————————————
9 / 30% – 5+ year patients survived 2006 Burzynski Antineoplastons (ANP) recurrent and progressive diffuse intrinsic BRAINSTEM GLIOMA (DBSG) (Pgs. 172-173)
======================================
� � � � � � � � � � � � � � � � �
======================================
SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
[2] 5/1/2010 – 6.9 months – Progression-Free Survival (PFS)
——————————————————————
[5] .10/21/2002 – 8 months – Overall Median Survival
——————————————————————
[3] 2/2008 – 9 months (3–36 months [3 years]) – Median Survival (MS)
——————————————————————
[2] 5/1/2010 – 9.15 months – Median Overall Survival
——————————————————————
[1] 4/2011 – 9.6 months – Median Time to Death
——————————————————————
[4] 1/1/2005 – 12 months (1 year) – Median Survival (MS)
——————————————————————
[6] .9/15/1999 – 12 months (1 year) – Overall Survival (5–104+ months [5 months – 8 years 8+ months])
======================================
2 YEARS 2.3 MONTHS MEDIAN SURVIVAL TIME (MST)
======================================
� � � � � � � � � � � � � � � � �
======================================
2006 – 26.3 months (2 years 2.3 months)Burzynski Antineoplastons (ANP) – Median Survival Time (MST): recurrent and progressive (RPS) tumors in children aged <4y: children less than 4 years old with inoperable BRAIN STEM GLIOMAS 2005 (Pg. 172)
======================================
� � � � � � � � � � � � � � � � �
======================================
3 YEARS MEDIAN OVERALL SURVIVAL FROM DIAGNOSIS (OSD)
======================================
� � � � � � � � � � � � � � � � �
======================================
2004 – 3 years – with treatment, may approach (Pg. 53)
——————————————————————
2004 – 3 years Burzynski Antineoplastons Median Overall Survival from Diagnosis (OSD): 6/1/2003 Protocol – HIGH-GRADE GLIOMA (Pg. 53)
======================================
� � � � � � � � � � � � � � � � �
======================================
5+ YEARS SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2006 – 5+ yearsBurzynski Antineoplastons: Survival in recurrent diffuse intrinsic GLIOBLASTOMAS and anaplastic ASTROCYTOMAS of the BRAINSTEM in a small group of Patients: BRAINSTEM GLIOMA (BSG) Patient with GLIOBLASTOMA (Pgs. 40 + 44-45)
======================================
� � � � � � � � � � � � � � � � �
======================================
6+ YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
7/2005 – 6+ yearsBurzynski Antineoplastons: Maximum Survival (MS): children less than 4 years old with inoperable BRAIN STEM GLIOMAs (BSG) BT-11 (study and Special Exception (SE)) (Pg. 300)
——————————————————————
6+ yearsBurzynski Antineoplastons Patient with recurrent, diffuse, intrinsic GLIOBLASTOMA MULTIFORME (GBM)
======================================
� � � � � � � � � � � � � � � � �
======================================
6.3 YEARS MEDIAN OVERALL SURVIVAL FROM DIAGNOSIS (OSD)
======================================
� � � � � � � � � � � � � � � � �
======================================
2004 – 6.3 yearsBurzynski Antineoplastons: Median Overall Survival from Diagnosis (OSD): 6/1/2003 Protocols – LOW-GRADE GLIOMA IN CHILDREN (Pg. 50)
======================================
� � � � � � � � � � � � � � � � �
======================================
7+ YEARS LONGEST / MAXIMUM SURVIVAL
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2004 – 7+ yearsBurzynski Antineoplastons: Longest Survival (the Patients are currently alive): Protocol – subgroup very difficult to treat recurrent diffuse intrinsic BRAIN STEM GLIOMA (Pg. 52)
——————————————————————
2006 – 7+ yearsBurzynski Antineoplastons (ANP) – Maximum Survival (MS): children aged <4 years diagnosed with diffuse intrinsic BRAIN STEM GLIOMA (DBSG) treated with ANP (Pg. 173)
======================================
� � � � � � � � � � � � � � � � �
======================================
7.5+ YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
2004 – 7.5+ yearsBurzynski Antineoplastons Maximum Survival (MS): 6/1/2003 Protocol – BT-11 BRAIN STEM GLIOMA (Pg. 51)
======================================
� � � � � � � � � � � � � � � � �
======================================
9+ YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
10/2006 – 9+ yearsBurzynski Antineoplastons: Maximum Survival Rate: Protocol – BT-11 BRAINSTEM GLIOMAS and multicentric tumors (MBSG) (Pg. 466)
======================================
� � � � � � � � � � � � � � � � �
======================================
11 YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
10/2004..11 yearsBurzynski Antineoplastons: Maximum Survival: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG): Special Exception (SE): (high-grade diffuse intrinsic BRAIN STEM GLIOMA (DBSG) recurrent after radiation and chemotherapy) (Pg. 386)
======================================
� � � � � � � � � � � � � � � � �
======================================
12.5+ YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
2004 – 12.5+ yearsBurzynski Antineoplastons: Maximum Survival (MS): 6/1/2003 Protocol – HIGH-GRADE GLIOMA (Pg. 53)
======================================
� � � � � � � � � � � � � � � � �
======================================
15.5+ YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
10/2004 – 15.5+ yearsBurzynski Antineoplastons: Maximum Survival: Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG): (high-grade diffuse intrinsic BRAIN STEM GLIOMA (DBSG) recurrent after radiation and chemotherapy) (Pg. 386)
======================================
� � � � � � � � � � � � � � � � �
======================================
17+ YEARS MAXIMUM SURVIVAL (MS)
======================================
� � � � � � � � � � � � � � � � �
======================================
3/2006 – 17+ years (approaching 18 years)Burzynski Antineoplastons: BRAINSTEM GLIOMA (BSG) Maximum Survival for Patient with recurrent, diffuse, intrinsic anaplastic ASTROCYTOMA (Pgs. 40 + 44-45)
======================================
� � � � � � � � � � � � � � � � �
======================================
Burzynski: BRAINSTEM GLIOMAs (DBSG):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/31/burzynski-brainstem-gliomas-dbsg/
======================================
References:
======================================
[1] 4/2011 – children with newly diagnosed diffuse intrinsic pontine gliomas
======================================
Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group
http://www.ncbi.nlm.nih.gov/pubmed/21345842/
Neuro Oncol. 2011 Apr;13(4):410-6. doi: 10.1093/neuonc/noq205. Epub 2011 Feb.22
http://www.ncbi.nlm.nih.gov/m/pubmed/21345842/
Neuro-oncology 2011 Apr; 13(4):410-6
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064697/
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064697/pdf/noq205.pdf
the Children’s Oncology Group
http://m.neuro-oncology.oxfordjournals.org/content/13/4/410.long?view=long&pmid=21345842
open-label phase II study (ACNS0126)
7/6/2004-9/6/2005
======================================
[2] 5/1/2010 – Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
======================================
Prospective Evaluation of Radiotherapy With Concurrent and Adjuvant Temozolomide in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
http://www.ncbi.nlm.nih.gov/pubmed/19647954/
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):113-8. doi: 10.1016/j.ijrobp.2009.04.031. Epub 2009 Aug 3
http://www.ncbi.nlm.nih.gov/m/pubmed/19647954/
International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 1 , Pages 113-118, 1 May 2010
http://www.redjournal.org/article/S0360-3016(09)00597-5/abstract
published online 03 August 2009
Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India
Presented at the Eighth Congress of the European Association for Neuro-Oncology, Barcelona, Spain, September 12–14, 2008
3/2005-11/2006
======================================
[3] 2/2008 – children with diffuse intrinsic brain stem glioma
======================================
Research Article
Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: A Children’s Oncology Group phase II study
http://www.ncbi.nlm.nih.gov/pubmed/17278121/
Pediatr Blood Cancer. 2008 Feb;50(2):227-30
http://www.ncbi.nlm.nih.gov/m/pubmed/17278121/
Pediatr Blood Cancer 2008;50:227–230
http://onlinelibrary.wiley.com/doi/10.1002/pbc.21154/abstract
Pediatric Blood & Cancer
Volume 50, Issue 2, pages 227–230, February 2008
http://onlinelibrary.wiley.com/doi/10.1002/pbc.21154/abstract;jsessionid=1C9E44F96D6558468F0D7EB45D50FE23.d04t03
Pediatric Blood & Cancer
Volume 50, Issue 2, Article first published online: 2 FEB 2007
http://onlinelibrary.wiley.com/doi/10.1002/pbc.21154/full
The Pediatric Oncology Group (POG, now part of the Children’s Oncology Group)
http://onlinelibrary.wiley.com/doi/10.1002/pbc.21154/pdf
DOI 10.1002/pbc.21154
http://radonc.ucsd.edu/patient-info/treatment-options/cancer-types/pediatric-cancers/Documents/Pediatric-Paper-04.pdf
University of Rochester Medical Center, Rochester, New York, USA
======================================
[4] 1/1/2005 – newly diagnosed diffuse brainstem glioma in children
======================================
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children:
results of a multiinstitutional study (SJHG-98)
http://www.ncbi.nlm.nih.gov/pubmed/15565574
Cancer. 2005 Jan 1;103(1):133-9.
http://www.ncbi.nlm.nih.gov/m/pubmed/15565574
Cancer 103, 133-139
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/abstract;jsessionid=6717837591CCC8FCBD8E46163808E221.d03t01
Cancer
Volume 103, Issue 1, pages 133–139, 1 January 2005
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/full
Article first published online: 24 NOV 2004
References:
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/references
Cited By:
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/citedby
DOI: 10.1002/cncr.20741
Department of Hematology-Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
======================================
[5] .10/21/2002 – paediatric pontine glioma
======================================
Treatment of paediatric pontine glioma with oral trophosphamide and etoposide
http://www.ncbi.nlm.nih.gov/pubmed/12434281/
Br J Cancer. 2002 Oct 21;87(9):945-9
http://www.ncbi.nlm.nih.gov/m/pubmed/12434281/
British Journal of Cancer (2002) 87, 945–949. doi:10.1038/sj.bjc.6600552
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364312/
Published online 21 October 2002
http://www.nature.com/bjc/journal/v87/n9/full/6600552a.html
St. Hedwigs Klinik, Hämato/Onkologie, Steinmetzstr. 1–3, Regensburg, Germany
http://www.nature.com/bjc/journal/v87/n9/pdf/6600552a.pdf
======================================
[6] .9/15/1999 – brainstem gliomas
======================================
A Phase I/II study of carboplatin combined with hyperfractionated radiotherapy for
brainstem gliomas

http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19990915)86:6%3C1064::AID-CNCR24%3E3.0.CO;2-1/full
Cancer 1999;86:1064–9
1999 American Cancer Society
Cancer
Volume 86, Issue 6, pages 1064–1069, 15 September 1999
Article first published online: 20 NOV 2000
DOI: 10.1002/(SICI)1097-0142(19990915)86:63.0.CO;2-1
======================================
[7] 3/15/1999 children with newly diagnosed diffuse intrinsic brainstem tumors
======================================
There is no role for hyperfractionated radiotherapy in the management of
children with newly diagnosed diffuse intrinsic brainstem tumors
: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy
http://www.ncbi.nlm.nih.gov/pubmed/10192340/
Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64
http://www.ncbi.nlm.nih.gov/m/pubmed/10192340/
International Journal of Radiation Oncology * Biology * Physics
Volume 43, Issue 5 , Pages 959-964, 15 March 1999
http://www.redjournal.org/article/S0360-3016(98)00501-X/abstract
Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY 10029-6574, USA
======================================
[8] 1/1998 – children with newly diagnosed diffuse pontine gliomas
======================================
Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study
http://www.ncbi.nlm.nih.gov/pubmed/9371386/
Med Pediatr Oncol. 1998 Jan;30(1):28-33
http://www.ncbi.nlm.nih.gov/m/pubmed/9371386/
Medical and Pediatric Oncology
Volume 30, Issue 1, pages 28–33, January 1998
http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1096-911X(199801)30:13.0.CO;2-2/abstract;jsessionid=94E4BFEF2606B89ADDD9682528353D47.d03t02
Article first published online: 7 DEC 1998
http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1096-911X(199801)30:13.0.CO;2-2/pdf
DOI: 10.1002/(SICI)1096-911X(199801)30:13.0.CO;2-2
Department of Hematology-Oncology, St. Jude Children’s Research Hospital, University of Tennessee, Memphis, USA
Pediatric Oncology
======================================
[9] .9/15/1994 – children with brain stem gliomas
======================================
Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial
http://www.ncbi.nlm.nih.gov/pubmed/8082086/
Cancer. 1994 Sep 15;74(6):1827-34
http://www.ncbi.nlm.nih.gov/m/pubmed/8082086/
Department of Neurology, Children’s National Medical Center, Washington, DC
======================================
� � � � � � � � � � � � � � � � �
======================================
The Burzynski Skeptics:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/18/the-burzynski-skeptics/
======================================
Perfessor Robert J. (Bob) Blaskiewicz Blatherskitewicz:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/31/the-burzynski-b-s-app/
======================================
Bob Blaskiewicz (Blatherskitewicz), Faux Skeptic Exposed!:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/07/bob-blaskiewicz-blatherskitewicz-faux-skeptic-exposed/
======================================
Critiquing the #SkepticCanary: “The Skeptics™” (SkeptiCowards©) Bob Blatherskitewicz and the so-called, “self-proclaimed” “CANCER RESEARCHER”:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/03/critiquing-the-skepticcanary-the-skeptics-skepticowards-bob-blatherskitewicz-and-the-so-called-self-proclaimed-cancer-researcher/
======================================
Critiquing Bob Blaskiewicz (#Burzynski Cancer is Serious Business, Part II):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/26/critiquing-bob-blaskiewicz-burzynski-cancer-is-serious-business-part-ii/
======================================
My Critique of Bob Blaskiewicz (Colorado Public Television – PBS CPT12):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/26/my-critique-of-bob-blaskiewicz-colorado-public-television-pbs-cpt12/
======================================
“The Skeptics” (Burzynski: Cancer is Serious Business, Part II):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/24/the-skeptics/
======================================
� � � � � � � � � � � � � � � � �

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s